00:00Jerry, how much of this is just about building out a robust portfolio that's not just dependent on obesity medication?
00:07Yeah, I think with this deal, we're really seeing Eli Lilly trying to, you know, transform its business and rely
00:15less on just, you know, diabetes and its weight loss drugs that it's well known for.
00:21You know, interestingly, Lilly has a long history in infectious diseases.
00:25You know, many, many decades ago, it made a treatment for penicillin and a polio vaccine.
00:32But the company is really, in recent years, focused in other areas.
00:37And now it's, you know, flush with cash from the success of its weight loss drugs.
00:42And it's now reentering the vaccine business, which has been a really challenging business for other companies.
00:50I got to ask about this new cholesterol treatment.
00:53It's like a gene editing treatment that apparently is a four-hour intravenous injection and then done, right?
01:04And that should lower your bad cholesterol for at least 18 months, but potentially the rest of your life.
01:10And I've had, you know, PR professionals emailing me ever since these results came out saying, like, this is game
01:18-changing and even bigger than GLP-1s.
01:21Is that hype for real?
01:24You know, we have to see still.
01:27So this is a company, you know, that Lilly bought called Verve.
01:31And they have been working on gene editing treatments.
01:34So this is a one-time treatment that could potentially lower your cholesterol, potentially for your entire life.
01:41You know, the results we saw are very promising.
01:44I think the big question here is there are a lot of other medicines out there for people who have
01:51high cholesterol.
01:52There's statins.
01:53There's other treatments that you can take even less frequently than statins.
01:58So, you know, this is a treatment that's showing promising results.
02:02I think it's more of a question is if it gets approved, whether people are willing to, you know, get
02:08this one-time treatment or if they're more comfortable with the existing medicines that they have to take more frequently.
02:13Jerry, does this speak also to the advancements in gene therapy as well as a treatment?
02:21Yeah, I mean, this is an area that Lilly has been really investing in.
02:24We've seen other large pharmaceutical companies that have gotten away from gene therapy.
02:29But, you know, this is an area that's shown a lot of promise.
02:33The idea is that you're editing someone's DNA and really getting to the root cause of a disease.
02:40And instead of taking a medicine every couple weeks or every couple months, you get one treatment and, you know,
02:47the effects potentially could last for your entire life.
02:51But it's still early days.
02:53The long-term data we haven't seen yet, so we don't really know the durability of a lot of these
02:58one-time treatments.
03:00But this is an area that Lilly clearly believes in and has been investing a lot in as well.
Comments